EMAIL THIS PAGE TO A FRIEND

Sleep medicine

Management of restless legs syndrome by the partial D2-agonist terguride.


PMID 14592288

Abstract

Terguride as a partial D2-receptors agonist seems suitable for treatment of restless legs syndrome (RLS). Nine RLS patients without previous dopaminergic therapy received a daily dose of terguride (0.25 mg) 29.9+/-16.9 (SD) days. Two patients enrolled in the study failed to turn up for a successive check up. The seven subjects who were re-examined complied with the therapy. Their RLS symptoms improved (as measured on the International RLS intensity scale), decreasing from 24.3+/-5.3 to 14+/-4.7 (p=0.014). However, the terguride treatment did not significantly alter the daytime sleepiness or the subjective duration of nocturnal sleep. The daily dose was doubled in three patients who reported insufficient RLS improvement. One of the three patients later reported augmentation.